SC
ATXS

Stempoint Capital’s Astria Therapeutics ATXS Stock Holding History

Stempoint Capital’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-56,287
Closed -$619K – 58
2024
Q3 		$619K Buy
+56,287
New +$626K 0.19% 49
2024
Q2 		– Sell
-230,273
Closed -$2.68M – 48
2024
Q1 		$2.68M Sell
230,273
-626,679
-73% -$7.8M 0.71% 34
2023
Q4 		$6.16M Buy
+856,952
New +$4.74M 1.64% 24

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Stempoint Capital's ATXS Position: Q4 2024 in Review

Stempoint Capital sold out of Astria Therapeutics (ATXS) in Q4 2024, closing a stake of 56,287 shares — an estimated $619K sold.

Stempoint Capital first reported a position in ATXS in Q4 2023 and held it in 3 quarters. The position peaked at $6.16M in Q4 2023. 110 funds tracked by Wall St. Rank hold ATXS as of Q4 2024.

  • Stempoint Capital reported no remaining Astria Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Stempoint Capital sold 56,287 Astria Therapeutics shares in Q4 2024, an estimated $619K.
  • Stempoint Capital first reported a position in Astria Therapeutics in Q4 2023 and held it in 3 quarters.
  • Stempoint Capital's Astria Therapeutics position peaked at $6.16M in Q4 2023.
  • 110 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2024.

Based on Stempoint Capital's 13F filing for Q4 2024, filed 14 Feb 2025.